Acceleron Pharma Chief Medical Officer Sherman Plans Retirement

Matthew Sherman, chief medical officer of Acceleron Pharma (NASDAQ: [[ticker:XLRN]]), plans to retire from the Cambridge, MA-based drug developer. Acceleron says Sherman won’t step away until after the company releases initial data from the Phase 3 study for luspatercept, a drug it is testing in partnership with Celgene (NASDAQ: [[ticker:CELG]]) as a treatment for a rare type of anemia. Sherman will continue as an advisor to Acceleron following his retirement. The company has started a search for Sherman’s successor.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.